Safety and Efficacy Study of Inhaled Carbon Monoxide to Treat Acute Respiratory Distress Syndrome (ARDS)
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study will be a multi-center, prospective, randomized, partially double-blind,
placebo-controlled Phase II clinical trial of inhaled CO (iCO) for the treatment of ARDS. The
trial will be conducted at 7 tertiary care medical centers including Weill Cornell
Medicine/NewYork-Presbyterian Hospital, Brigham and Women's Hospital (BWH), Massachusetts
General Hospital (MGH), Duke University Hospital, Durham Veterans Administration Medical
Center, New York-Presbyterian Brooklyn Methodist Hospital, and Duke Regional Hospital. The
purpose of this study is to evaluate the safety, tolerability, and efficacy of inhaled carbon
monoxide (iCO) for the treatment of ARDS and to examine the biologic readouts of low dose iCO
therapy in patients with ARDS
Phase:
Phase 2
Details
Lead Sponsor:
Brigham and Women's Hospital
Collaborators:
Duke Regional Hospital Duke University Durham VA Medical Center Massachusetts General Hospital New York Presbyterian Brooklyn Methodist Hospital U.S. Army Medical Research Acquisition Activity Weill Medical College of Cornell University